Kwok J C, Richardson D R
The Iron Metabolism and Chelation Group, The Heart Research Institute, Sydney, New South Wales, Australia.
Redox Rep. 2000;5(6):317-24. doi: 10.1179/135100000101535898.
The cardiotoxic effect of anthracyclines limits their use in the treatment of a variety of cancers. The reason for the high susceptibility of cardiac muscle to anthracyclines remains unclear, but it appears to be due, at least in part, to the interaction of these drugs with intracellular iron (Fe). The suggestion that Fe plays an important role in anthracycline cardiotoxicity has been strengthened by observation that the chelator, dexrazoxane (ICRF-187), has a potent cardioprotective effect. In the present review, the role of Fe in the cardiotoxicity of anthracyclines is discussed together with the possible role of Fe chelation therapy as a cardioprotective strategy that may also result in enhanced antitumour activity.
蒽环类药物的心脏毒性作用限制了它们在多种癌症治疗中的应用。心肌对蒽环类药物高度敏感的原因尚不清楚，但至少部分原因似乎是这些药物与细胞内铁（Fe）的相互作用。螯合剂右丙亚胺（ICRF - 187）具有强大的心脏保护作用，这一观察结果进一步支持了铁在蒽环类药物心脏毒性中起重要作用的观点。在本综述中，我们将讨论铁在蒽环类药物心脏毒性中的作用，以及铁螯合疗法作为一种心脏保护策略可能发挥的作用，这种策略还可能增强抗肿瘤活性。
